Abstract:Increasing accumulation and retention of nanomedicines within tumor tissue is a significant challenge, particularly in the case of brain tumors where access to the tumor through the vasculature is restricted by the blood-brain barrier (BBB). This makes the application of nanomedicines in neuro-oncology often considered unfeasible, with efficacy limited to regions of significant disease progression and compromised BBB. However, little is understood about how the evolving tumor-brain physiology during disease progression affects the permeability and retention of designer nanomedicines. We report here the development of a modular nanomedicine platform that, when used in conjunction with a unique model of how tumorigenesis affects BBB integrity, allows investigation of how nanomaterial properties affect uptake and retention in brain tissue. By combining different in vivo longitudinal imaging techniques (including positron emission tomography and magnetic resonance imaging), we have evaluated the retention of nanomedicines with predefined physicochemical properties (size and surface functionality) and established a relationship between structure and tissue accumulation as a function of a new parameter that measures BBB leakiness; this offers significant advancements in our ability to relate tumor accumulation of nanomedicines to more physiologically relevant parameters. Our data show that accumulation of nanomedicines in brain tumor tissue is better correlated with the leakiness of the BBB than actual tumor volume. This was evaluated by establishing brain tumors using a spontaneous and endogenously derived glioblastoma model providing a unique opportunity to assess these parameters individually and compare the results across multiple mice. We also quantitatively demonstrate that smaller nanomedicines (20 nm) can indeed cross the BBB and accumulate in tumors at earlier stages of the disease than larger analogues, therefore opening the possibility of developing patient-specific nanoparticle treatment interventions in earlier stages of the disease. Importantly, these results provide a more predictive approach for designing efficacious personalized nanomedicines based on a particular patient's condition.

Autocatalytic Delivery of Brain Tumor-Targeting, Size-Shrinkable Nanoparticles for Treatment of Breast Cancer Brain Metastases

Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure Against Glioblastoma

Escape from Abluminal LRP1-mediated Clearance for Boosted Nanoparticle Brain Delivery and Brain Metastasis Treatment

PSMA-targeted nanoparticles for specific penetration of blood-brain tumor barrier and combined therapy of brain metastases

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

Catalytic Modulation of the Tumor Microenvironment Using Cascade Enzymes for Synergistic Boron Neutron Capture Therapy in the Treatment of Gliomas

Micro‐Nanocarriers Based Drug Delivery Technology for Blood‐Brain Barrier Crossing and Brain Tumor Targeting Therapy (small 45/2022)

Autocatalytic, Brain Tumor‐Targeting Delivery of Bardoxolone Methyl Self‐Assembled Nanoparticles for Glioblastoma Treatment

A Therapeutic Sheep in Metastatic Wolf’s Clothing: Trojan Horse Approach for Cancer Brain Metastases Treatment

Dual Targeting Micelles Loaded with Paclitaxel and Lapatinib for Combinational Therapy of Brain Metastases from Breast Cancer.

All-stage targeted therapy for the brain metastasis from triple-negative breast cancer

Understanding the Uptake of Nanomedicines at Different Stages of Brain Cancer Using a Modular Nanocarrier Platform and Precision Bispecific Antibodies.

Blood-brain barrier and blood-brain tumor barrier penetrating peptide-drug conjugate as targeted therapy for the treatment of lung cancer brain metastasis

A Multistage‐Responsive Antibody‐Delivery Strategy to Improve Immunotherapy for NSCLC Brain Metastasis by Ultrasensitive Releasing and Tumor‐Anchoring

LRP1-upregulated Nanoparticles for Efficiently Conquering the Blood-Brain Barrier and Targetedly Suppressing Multifocal and Infiltrative Brain Metastases

Treating Metastatic Triple Negative Breast Cancer with CD44/neuropilin Dual Molecular Targets of Multifunctional Nanoparticles.

<i>In Situ</i> Formation of Nanotheranostics to Overcome the Blood-Brain Barrier and Enhance Treatment of Orthotopic Glioma

Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases

Lapatinib-loaded Human Serum Albumin Nanoparticles for the Prevention and Treatment of Triple-Negative Breast Cancer Metastasis to the Brain

Nanoparticle Strategies to Improve the Delivery of Anticancer Drugs across the Blood-Brain Barrier to Treat Brain Tumors.

Targeted Delivery of Chemo-Sonodynamic Therapy via Brain Targeting, Glutathione-Consumable Polymeric Nanoparticles for Effective Brain Cancer Treatment